Future Oncology, Ahead of Print.
Thu Nov 14, 2019 07:01
Future Oncology, Ahead of Print.
Thu Nov 14, 2019 06:30
The NSD family of histone lysine methyltransferases have emerged as important biomarkers that participate in a variety of malignancies. Recent evidence has indicated that somatic dysregulation of the nuclear r...
Thu Nov 14, 2019 02:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Thu Nov 14, 2019 10:00
Cancers, Vol. 11, Pages 1795: Emodin Inhibits EBV Reactivation and Represses NPC Tumorigenesis Cancers doi: 10.3390/cancers11111795 Authors: Chung-Chun Wu Mei-Shu Chen Yu-Jhen Cheng Ying-Chieh Ko Su-Fang Lin Ing-Ming Chiu Jen-Yang Chen Nasopharyngeal carcinoma (NPC) is a unique malignancy derived from the epithelium of the nasopharynx. Despite great advances in the development of radiotherapy and chemotherapy, relapse and metastasis in NPC patients remain major causes...
02:00
PURPOSE: The heterodimeric transcription factor HIF-2 is arguably the most important driver of clear cell renal cell carcinoma (ccRCC). While considered undruggable, structural analyses at UT Southwestern Medical Center (UTSW) identified a vulnerability in the a subunit, which heterodimerizes with HIF-1b, ultimately leading to the development of PT2385, a first-in-class inhibitor. PT2385 was safe and active in a first-in-human phase I clinical trial of extensively pretreated ccRCC patients at UTSW...
Thu Nov 14, 2019 17:00
Purpose: To determine the efficacy of the therapeutic DNA vaccine GX-188E for inducing regression of cervical intraepithelial neoplasia (CIN) 3. Experimental Design: We conducted a prospective, randomized, multicenter, open-label, phase 2 clinical trial of GX-188E in CIN3 patients positive for HPV type 16/18. The primary endpoint was to determine the histopathological regression to less than or equal to CIN1 at visit 7 (V7; 20 weeks after the first GX-188E injection), and an extension study was...
Thu Nov 14, 2019 16:00
Purpose: Aflibercept is a targeted anti-vascular endothelial growth factor (VEGF) therapy used to treat patients with metastatic colorectal cancer (mCRC) following progression on oxaliplatin-based regimens. This post hoc study evaluated the effect of prior bevacizumab treatment and growth factor levels on patient outcomes associated with aflibercept in the VELOUR Phase III trial. Experimental Design: Baseline biomarker plasma concentrations were measured using a bead-based multiplex assay. Patients...
Thu Nov 14, 2019 16:00
Endocrine therapy is important for management of patients with estrogen receptor (ER) positive breast cancer, however positive ER staining does not reliably predict therapy response. We assessed the potential to improve prediction of response to endocrine treatment of a novel test that quantifies functional ER pathway activity from mRNA levels of ER pathway-specific target genes. ER pathway activity was assessed on datasets from three neoadjuvant treated ER-positive breast cancer patient cohorts....
Thu Nov 14, 2019 17:01
Gliomas are the second most common primary brain tumors in adults. They are treated with combination therapies including surgery, radiotherapy, and chemotherapy. There are currently limited treatment options for recurrent gliomas, and new targeted therapies need to be identified, especially in glioblastomas, which have poor prognosis. Isocitrate dehydrogenase (IDH) mutations are detected in various tumors, including gliomas. Most IDH mutant glioma patients harbor the IDH1R132H subtype. Mutant IDH...
Thu Nov 14, 2019 17:01
British Journal of Cancer, Published online: 15 November 2019; doi:10.1038/s41416-019-0630-3Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
02:00
Corrigendum to “Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers” by G Liu et al. J Natl Cancer Inst 2015; 107(7):doi:10.1093/jnci/djv108
Thu Oct 17, 2019 03:00
Abstract Objectives Treatment-induced lesions represent a great challenge in neuro-oncology. The aims of this study were (i) to characterize treatment induced lesions in glioblastoma patients treated with chemoradiotherapy and heat-shock protein (HSP) vaccine and (ii) to evaluate the diagnostic accuracy of diffusion weighted imaging for differentiation between treatment-induced lesions and tumor progression. ...
Thu Nov 14, 2019 02:00
Breast cancer (BC) radiotherapy (RT) can induce cardiotoxicity, with adverse events often observed many years after BC RT. Subclinical left ventricular (LV) dysfunction can be detected early after BC RT with g...
Thu Nov 14, 2019 02:00
To determine the prognostic effect of adjuvant radiation and clinicopathological variables in surgically treated patients with small cell carcinoma of the cervix (SCCC).
Wed Nov 13, 2019 02:00
This retrospective German and Italian multicenter analysis aimed to compare the role of normofractionated stereotactic radiotherapy (nFSRT) to CyberKnife-based hypofractionated stereotactic radiotherapy (CK-hF...
Tue Nov 12, 2019 02:00
The objective of this investigation is to evaluate the outcomes and toxicity of carbon-ion re-irradiation (CIR) in patients with rare head and neck cancers (HNC). There is a paucity of data regarding treatment...
Tue Nov 12, 2019 02:00
The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 f...
Tue Nov 12, 2019 02:00
Publication date: December 2019Source: European Journal of Cancer, Volume 123Author(s): Atul Sharma, Bidhu Kalyan Mohanti, Surendra Pal Chaudhary, V. Sreenivas, Ranjit Kumar Sahoo, Nootan Kumar Shukla, Sanjay Thulkar, Sujoy Pal, Surya V. Deo, Sushmita Pathy, Nihar Ranjan Dash, Sunil Kumar, Sushma Bhatnagar, Rakesh Kumar, Seema Mishra, Peush Sahni, Venkateswaran K. Iyer, Vinod RainaAbstractAimTo determine equivalence of modified gemcitabine and oxaliplatin compared with gemcitabine and cisplatin in...
Thu Nov 14, 2019 18:53
Abstract Introduction Diffuse intrinsic pontine glioma (DIPG) is the most common form of brainstem glioma. The present study was performed to assess if hypofractionated radiotherapy completed in < 3 weeks with temozolomide improves survival in DIPG. Material and methods The present study is a phase II open label randomized trial. The study included newly...
Thu Nov 14, 2019 02:00
Abstract Purpose Concurrent chemoradiotherapy (CCRT) is one of the standard treatments for patients with advanced head and neck squamous cell carcinoma (HNSCC). However, CCRT may lead to decreased quality of life (QoL) and treatment compliance. This study aimed to determine the effects of PG2 (Astragalus polysaccharides) injection on CCRT-associated adverse events (AEs) and patients’ compliance with the CCRT course. ...
Thu Nov 14, 2019 02:00
Cancers, Vol. 11, Pages 1794: HDAC Inhibitors in Acute Myeloid Leukemia Cancers doi: 10.3390/cancers11111794 Authors: San José-Enériz Gimenez-Camino Agirre Prosper Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled proliferation, differentiation arrest, and accumulation of immature myeloid progenitors. Although clinical advances in AML have been made, especially in young patients, long-term disease-free survival remains poor, making...
Thu Nov 14, 2019 02:00
20 years of rituximab treatment: what have we learnt? Future Oncol. 2019 Nov 13;: Authors: Renner C PMID: 31718346 [PubMed - as supplied by publisher]
Thu Nov 14, 2019 16:10
Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases. Future Oncol. 2019 Nov 13;: Authors: Jurczak W, Cohen S, Illidge TM, Silva AD, Amersdorffer J Abstract Sandoz rituximab (SDZ-RTX; Rixathon®; GP2013), a rituximab biosimilar, was approved in June 2017 in Europe in all indications of reference rituximab. The stepwise SDZ-RTX development program generated extensive physicochemical,...
Thu Nov 14, 2019 16:10
Cancers, Vol. 11, Pages 1793: Proteostasis In The Endoplasmic Reticulum: Road to Cure Cancers doi: 10.3390/cancers11111793 Authors: Nam Jeon The endoplasmic reticulum (ER) is an interconnected organelle that is responsible for the biosynthesis, folding, maturation, stabilization, and trafficking of transmembrane and secretory proteins. Therefore, cells evolve protein quality-control equipment of the ER to ensure protein homeostasis, also termed proteostasis. However, disruption...
Thu Nov 14, 2019 02:00
Publication date: Available online 13 November 2019Source: Critical Reviews in Oncology/HematologyAuthor(s): Muge Akbulut, Yuksel UrunAbstractAlthough over the past few decades cardiovascular disease (CVD) mortality has been decreasing, along with cancer it is still the leading cause of mortality in developed countries. Because of similar etiological risk factors such as smoking, advanced age, and obesity, the coincidence of cancer and CVD is a common situation that is associated with polypharmacy...
Thu Nov 14, 2019 14:28
Publication date: Available online 13 November 2019Source: Critical Reviews in Oncology/HematologyAuthor(s): Eiman Y. Ibrahim, Barbara E. EhrlichAbstractChemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of chemotherapy that is frequently experienced by patients receiving treatment for cancer. CIPN is caused by many of the most commonly used chemotherapeutic agents, including taxanes, vinca alkaloids, and bortezomib. Pain and sensory abnormalities may persist for months, or even...
Thu Nov 14, 2019 14:28
Abstract Objective This pilot study aimed to evaluate the feasibility, acceptability, and psychosocial outcomes of a text‐based online group therapy intervention, i‐Restoring Body Image after Cancer (i‐ReBIC). i‐ReBIC was developed to reduce body image distress and psychosexual dysfunction among women diagnosed and treated for breast or gynecological cancer. Methods i‐ReBIC was adapted from an empirically tested face‐to‐face group therapy intervention, ReBIC. Over the 8‐week intervention,...
Thu Nov 14, 2019 11:28
Cancers, Vol. 11, Pages 1790: Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations Cancers doi: 10.3390/cancers11111790 Authors: Matteo Cassina Luisa Frizziero Enrico Opocher Raffaele Parrozzani Ugo Sorrentino Elisabetta Viscardi Giacomo Miglionico Edoardo Midena Maurizio Clementi Eva Trevisson Type 1 neurofibromatosis (NF1) is a dominantly inherited condition predisposing to tumor...
Thu Nov 14, 2019 02:00
Cancers, Vol. 11, Pages 1791: Breast Cancer in Young Women: Status Quo and Advanced Disease Management by a Predictive, Preventive, and Personalized Approach Cancers doi: 10.3390/cancers11111791 Authors: Erik Kudela Marek Samec Peter Kubatka Marcela Nachajova Zuzana Laucekova Alena Liskova Karol Dokus Kamil Biringer Denisa Simova Eva Gabonova Zuzana Dankova Kristina Biskupska Bodova Pavol Zubor Daniela Trog Why does healthcare of breast cancer (BC)...
Thu Nov 14, 2019 02:00
Cancers, Vol. 11, Pages 1792: Animal Models of Hepatocellular Carcinoma Prevention Cancers doi: 10.3390/cancers11111792 Authors: Ram C. Shankaraiah Laura Gramantieri Francesca Fornari Silvia Sabbioni Elisa Callegari Massimo Negrini Hepatocellular carcinoma (HCC) is a deadly disease and therapeutic efficacy in advanced HCC is limited. Since progression of chronic liver disease to HCC involves a long latency period of a few decades, a significant window of therapeutic opportunities...
Thu Nov 14, 2019 02:00
Abstract Analysis of anti‐cancer immunity aids in assessing the prognosis of patients with breast cancer. From 250 operated breast cancers, we focused on serum levels of C‐C motif chemokine ligand 5 (CCL5), which is involved in cancer immune reactions. Serum levels of CCL5 were measured using a cytometric bead‐based immunoassay kit and CCL5 expression in cancer cells was determined using immunohistochemical staining. In addition, mRNA in cancer and stromal cells was analyzed by microdissection and...
Thu Nov 14, 2019 11:01
Publication date: Available online 14 November 2019Source: European Journal of Surgical OncologyAuthor(s): Aditi Bhatt, Yutaka Yonemura, Sanket Mehta, Nazim Benzerdjeb, Praveen Kammar, Loma Parikh, Mita Y. Shah, Sakina Shaikh BHMS, Aruna Prabhu, Suniti Mishra, Snita Sinukumar, Vahan Kepenekian, Naoual Bakrin, Guillaume Passot, Olivier GlehenAbstractBackgroundThe aim was to study the patterns of target region (greater omentum, lesser omentum, falciform and umbilical round ligament) involvement in...
Thu Nov 14, 2019 12:12
Publication date: Available online 14 November 2019Source: European Journal of Surgical OncologyAuthor(s): B.J.G.A. Corten, W.K.G. Leclercq, R.M.H. Roumen, P.H. van Zwam, C.H. Dejong, G.D. SlooterAbstractBackgroundIt was hitherto common practice to analyse each removed gallbladder for the presence of gall bladder cancer (GBC) although this approach may be questioned. The aim of this study was to determine whether a policy of selective histopathological analysis (Sel-HPA) is oncologically safe and...
Thu Nov 14, 2019 12:12
Cancers, Vol. 11, Pages 1789: Ionizing Radiation and Complex DNA Damage: From Prediction to Detection Challenges and Biological Significance Cancers doi: 10.3390/cancers11111789 Authors: Ifigeneia V. Mavragani Zacharenia Nikitaki Spyridon A. Kalospyros Alexandros G. Georgakilas Biological responses to ionizing radiation (IR) have been studied for many years, generally showing the dependence of these responses on the quality of radiation, i.e., the radiation particle type and...
Thu Nov 14, 2019 02:00
BACKGROUND Head and neck squamous cell carcinoma (HNSCC) is one of the most frequently diagnosed cancers worldwide. LOX‐like (LOXL) 2 (LOXL2) demonstrates alternative splicing events in patients with human papillomavirus (HPV)–negative HNSCC. The current study explored the role of a dominant LOXL2 variant in HPV‐negative HNSCC. METHODS Expression of the LOXL2 variant was analyzed using The Cancer Genome Atlas cohorts and validated using quantitative reverse transcriptase–polymerase chain reaction...
Wed Nov 13, 2019 17:27
Background Carfilzomib improves survival in patients with recurrent myeloma. Given the strict eligibility criteria in clinical trials, the actual frequency of cardiac adverse events (CAEs) and pulmonary adverse events (PAEs) and the risk factors associated with these AEs in the general population need to be established. Methods The authors extracted myeloma cases in the Surveillance, Epidemiology, and End Results (SEER)–Medicare linked database from 2000 through 2013 and corresponding claims...
Wed Nov 13, 2019 17:25
Background The current study was conducted to determine whether the incidence of late‐stage head and neck cancer (HNC) is decreasing and to estimate the risk of late‐stage HNC diagnosis based on race and sex. Methods Age‐adjusted incidence rates for patients aged ≥18 years with stage IV HNC were abstracted from the Surveillance, Epidemiology, and End Results database (2004‐2015). Rates were stratified by race, sex, and age. Joinpoint regression estimated annual percent changes (APCs) in rates...
Wed Nov 13, 2019 17:20
Adverse respiratory outcomes among head and neck cancer survivors in the Utah Cancer Survivors Study
Background The number of head and neck cancer (HNC) survivors has been increasing because of improving survival in the United States. The aim of this study was to evaluate the incidence of respiratory disease diagnoses in HNC survivors in comparison with cancer‐free individuals. A second aim was to investigate risk factors for respiratory disease among HNC survivors. Methods Patients with HNC diagnosed from 1996 to 2012 were identified in the Utah Cancer Registry (n = 1901). Up to 5 cancer‐free...
Wed Nov 13, 2019 17:18
Dose‐dense adjuvant chemotherapy is standard of care in high‐risk early breast cancer patients. However, its role in HER2‐positive patients is still uncertain. In this exploratory analysis of the GIM2 trial, we investigated the efficacy of dose‐dense chemotherapy in HER2‐positive breast cancer patients with or without exposure to trastuzumab. In the GIM2 trial, node‐positive early breast cancer patients were randomized to receive 4 cycles of (fluorouracil)epirubicin/cyclophosphamide followed by 4...
Wed Nov 13, 2019 19:20
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου